A China-based healthcare investment firm has launched a new US$100M VC fund focused on Seed to Series A opportunities in healthcare. Typical early-stage investment is US$5-10M. The firm prefers to lead in a financing round but is also open to co-investing. The firm is currently seeking opportunities from the US, China Europe and Israel.
When it comes to early-stage healthcare investments, the firm is extremely opportunistic across sectors. The firm’s focus is divided between 80 percent pharma and biotech, reserving 20 percent for devices, health care IT and services. In terms of disease areas, the firm prefers technologies targeting large unmet medical need and is less interested in rare diseases. The firm is seeking opportunities in Seed or Series A stage.
The firm is looking for experienced teams with strong sector expertise. As a China-based fund, the firm seeks to add value in the Chinese market through joint venture, registration expertise, and distribution channels.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org